Evotec (ETR:EVT) Share Price Crosses Below 50-Day Moving Average – Should You Sell?

Evotec SE (ETR:EVT) shares passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of €4.46 and traded as low as €3.45. Evotec shares last traded at €3.45, with a volume of 754,876 shares.

Evotec Stock Performance

The company has a debt-to-equity ratio of 55.38, a quick ratio of 2.97 and a current ratio of 1.68. The stock has a market cap of $636.79 million, a P/E ratio of -3.71, a price-to-earnings-growth ratio of 0.98 and a beta of 1.31. The company’s 50 day moving average price is €4.40 and its 200-day moving average price is €4.98.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.